Hemostemix Inc · TSXV:HEM
Hemostemix — Investor Presentation (2025)
22 slides from Hemostemix's investor presentation, Nov 3, 2025
Slide 1: Hemostemix Inc.
Hemostemix Inc. TSXV:HEM OTCQB:HMTXF FSE:2VF0
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward looking statements that reflect management’s Actual results, performance and achievement(s) could differ materially from that expectations regarding the future growth and results of operational performance expressed in, or implied by, any
Slide 3: Our Vision
OUR VISION Harness each patient’s own stem cells to heal ischemia and relieve pain—safely, ethically, and accessibly. Peripheral arterial disease? Diabetic foot ulcer? CLTI? Angina? Congestive Heart Failure? Ischemic Cardiomyopathy? Non ischemic Dilated Cardiomyopathy? Vascular Dementia? Total Body
Slide 4: Saving a Limb is Saving a Life!
T h r e e Q u e s t i o n s : 1 . D o e s i t w o r k ? 2 . P a t h t o M a r k e t ? 3 . E x i t Va l u a t i o n ? Saving a Limb is Saving a Life! Whereas the CLTI five-year mortality is 50%, the Universities of Toronto and British Columbia presented: 83% of patients followed in the Phase II trial
Slide 5: ACP-01 Heart Study
ACP-01 HEART STUDY, STEM CELL RESEARCH AND THERAPY, OCTOBER 2023 Retrospective analysis of 53 adult patients with severe cardiomyopathy, 41 ischemic, 8 non ischemic dilated cardiomyopathy. LVEF% measured at baseline, and at months 4 and 12. ISCHEMIC 1.LVEF% increased from 29.9% to 34.6% at month 4 (
Slide 6: It Works! Safety, Clinical Relevancy and Statistical Efficacy
IT WORKS! Safety, Clinical Relevancy and Statistical Efficacy 06
Slide 7: Production Agreement & Equity Investment
PAT H T O M A R K E T Production Agreement & Equity Investment CYTOIMMUNE PRODUCTION AGREEMENT 15 YEAR AGREEMENT WITH PUERTO RICO Fully funded two-year production agreement that includes $1.1 Act 60 legislation generates 50% cash back of all current and Million of Revenue, CytoImmune has a $27 Milli
Slide 8: Target Markets are Very Large
MARKETS Target Markets are Very Large CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE 2023 TO 2032 (USD BILLION) The global CLTI market was valued at $4.02 Billion in 2022. The Ischemic Heart Disease (IHD) drugs market 10 $9.18M reached US $6.1 Billion in 2022. 9 $8.53M $7.94M Addressable Market 8 $7.3
Slide 9: Highlights
HIGHLIGHTS The Company projects to be cashflow positive by Q4 2026 selling 20-30 treatments per month to: 1. no-option patients suffering from pain related to end-stage CLTI, ICM, DCM, CHF, total body ischemia, and chronic pain, in Florida. 2. Phase I patients who pay to be treated in the Bahamas 09
Slide 10: Forward Sales of Treatments
PAT H S T O M A R K E T S Forward Sales of Treatments 110 Heart 226 CLTI Invasive Cardiologists Phase II Vascular Surgeons Organized invasive cardiology capacity to treat up to 110 Globally, 236 million suffer from Peripheral Arterial Disease. patients/month with cardiologists who have completed App
Slide 11: A Multiple Treatments Technology Platform: ACP, NCP, CCP
P L AT F O R M T E C H N O L O G Y A Multiple Treatments Technology Platform: ACP, NCP, CCP Neuronal Cell Precursors From the patient’s blood: ACP, NCP, and CCP. Enhanced secretion of nerve growth factors, Homing of cells to site of injury. Neuro – regenerative! Small animal study of motor function
Slide 12: Key Process Steps with Treatment on Day 7
PROCESS Key Process Steps with Treatment on Day 7 ACP-01 (patient’s DNA) scales and ships in 3 x 10 cc ready to use syringes, to physicians globally. DAY 1 DAY 3 DAY 5 DAY 7 Blood collection Culturing and Quality Control release tests Administration of cells to and shipping differentiation of cells
Slide 13: Why Physicians and Patients Like ACP
Why Physicians and Patients Like ACP Heals No Ethical Ulcers Saves Concerns Limb Non-surgical High Cell restoration of Viability circulation Revenue 100% Safe Low Simple Patient Protocol Risks 13
Slide 14: Historical Event Timeline
TIMELINE Historical Event Timeline 3rd Heart Study 106 Subject ICH World Economic Retrospective Forum Technology PHASE 1 91st Patent Heart Study Pioneer Award CLI Study published issued Published 2003 2005 2006 2009 2013 2020 2022 2023 Hemostemix PHASE 1 PHASE 2 Founded 24 subject 1st Heart 2nd CLI
Slide 15: Autologous Regenerative Therapeutic Competitors
COMPETITORS Autologous Regenerative Therapeutic Competitors Company Indications Source Phase Ischemic Heart Chronic Limb Chronic Limb | || ||| Disease Threatening Ischemia Threatening Ischemia Hemostemix Peripheral Blood1 BioCardia Bone Marrow2 Life Cells3 Acellular Dermal Matrices3 BioGen Cells Per
Slide 16: Path to Market – No Option Patients
C L E A R PAT H T O M A R K E T Path to Market – No Option Patients Sales of ACP for no-option patient treatments ACP-01 heart disease treatments will be To-date, seven clinical trial sites have is through clinicians who have regulatory through invasive cardiologists who have the capacity to treat 3
Slide 17: Timeline to Production
TIMESCALES Timeline to Production ACP tech transfer is underway. Revenue from forward sales STAGE 06 First treatments in Q1 Up to 240 batches /month 2028 1 ACTS Module 1 Shift Q4 Production for Clinical Trials and Revenue STAGE 05 40 batches /month 2027 2 Teams 2 Shifts Production for Clinical Trial
Slide 18: Capital Table
PROFORMA Capital Table Hemostemix Inc. - Proforma Cap Table (Jan-13-2025) Shares 144,727,414 Notes: 1. CD2 – 5-yr secured (1st position), due April-2027, Warrants 78,489,650 interest of 8% p.a. payable in shares, converts at $0.175 per share. Options 12,386,694 2. Warrants – Weighted average strike
Slide 19: Use of Funds
USE OF FUNDS Cash Use - Manufacturing and Required Operating Costs Year 1 Year 2 Year 3 Year 4 Year 5 Use of Manufacturing Facility - (1 Clean Rm with 2 shifts; + working lab) Manufacturing - Costs+Staffing (add 2nd shift in 1yr-Q3) $1,591 $953 $1,053 $1,310 $1,053 $1,310 $1,053 $1,310 $1,053 $1,310
Slide 20: Key Takeaways
SUMMARY Key Takeaways ACP is a break-through treatment for no-option angina, dilated ACP is effective, and because it is sourced from the patient's and ischemic cardiomyopathy and CLTI, PAD, Vascular blood and cultured in the patient's serum. It is Dementia.. completely autologous and therefore safe
Slide 21: Exits & Comparables
E X I T S & C O M PA R A B L E S Life Sciences Investment 2024: $191B. 2024 M&A: 6 deals $2.4 B. Bristol Myers $13.8 Billion Cash for Myocardia…Compare Hemostemix? Myocardia's Results (Lancet) ACP-01 Results (Stem Cell Research & Therapy) 251 (59%) were enrolled and randomly assigned to mavacamten F
Slide 22: Thank You! Get in Touch!
T S X V: H E M OTCQB:HMTXF FSE:2VF0 Thank You! Get in Touch! Thomas Smeenk, CEO Cell: +1-905-580-4170 TSmeenk@Hemostemix.com 12 22